CD&R’s purchase, which was agreed last month, values Pharmedium at about $1bn according to Dow Jones.
Oak Investment Partners will also exit Pharmedium as part of the deal, while company CEO David Jonas will retain a stake through his JVC Management investment firm.
The company’s outsourced sterile compounding services are used by hospitals, primarily to facilitate ready-to-use intravenous drug delivery to patients.
Illinoi-based Pharmedium serves more than 2,600 acute-care hospitals, including integrated delivery systems, academic medical centres, hospital groups, and standalone urban, suburban and rural hospitals.
Copyright © 2014 AltAssets